Funding for this research was provided by:
Received: 9 December 2020
Accepted: 13 April 2021
First Online: 23 April 2021
: This study was part of a larger phase I, single-center, open-label study (EudraCT Number 2016-001190-32). Written informed consent was obtained for each subject. The study was approved by the local ethical committee and conducted in accordance with the most recent version of the Declaration of Helsinki.
: Written informed consent obtained for each subject included publication of their data and images.
: The study was sponsored by UCB Pharma, Belgium, who also delivered precursor and reference compound for [<sup>11</sup>C]-UCB-J. No other potential conflicts of interest relevant to this manuscript were reported.